Huang Y, Xu K, Wang W, Cui F, Zeng Y, Hao Z X, Cai W P, He J X, Liu J
Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China.
Zhonghua Zhong Liu Za Zhi. 2020 Sep 23;42(9):713-717. doi: 10.3760/cma.j.cn112152-20200330-00276.
Lung cancer is currently the malignant tumor with the highest morbidity and mortality in the world, and the main type is non-small cell lung cancer. Immune checkpoint inhibitor is a landmark discovery in the history of cancer treatment, which rewrites the history of cancer treatment, and improves the medical treatment of advanced tumors by a big step forward. The article summarizes the research progress of therapeutic drugs against anti-programmed cell death protein and programmed cell death protein ligand antibodies in the clinical diagnosis and treatment of non-small cell lung cancer. The principle of drug action, the differences in the diagnosis and treatment of non-small cell lung cancer in different clinical stages, and future research directions are discussed to provide the usage guidelines of immune checkpoint inhibitors for clinical oncologists.
肺癌是目前全球发病率和死亡率最高的恶性肿瘤，主要类型为非小细胞肺癌。免疫检查点抑制剂是癌症治疗史上具有里程碑意义的发现，它改写了癌症治疗的历史，使晚期肿瘤的医学治疗向前迈进了一大步。本文综述了抗程序性细胞死亡蛋白和程序性细胞死亡蛋白配体抗体治疗药物在非小细胞肺癌临床诊断和治疗中的研究进展。讨论了药物作用原理、不同临床分期非小细胞肺癌诊疗的差异以及未来的研究方向，为临床肿瘤学家提供免疫检查点抑制剂的使用指南。
